BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mueller YM, Schrama TJ, Ruijten R, Schreurs MWJ, Grashof DGB, van de Werken HJG, Lasinio GJ, Álvarez-Sierra D, Kiernan CH, Castro Eiro MD, van Meurs M, Brouwers-Haspels I, Zhao M, Li L, de Wit H, Ouzounis CA, Wilmsen MEP, Alofs TM, Laport DA, van Wees T, Kraker G, Jaimes MC, Van Bockstael S, Hernández-González M, Rokx C, Rijnders BJA, Pujol-Borrell R, Katsikis PD. Stratification of hospitalized COVID-19 patients into clinical severity progression groups by immuno-phenotyping and machine learning. Nat Commun 2022;13:915. [PMID: 35177626 DOI: 10.1038/s41467-022-28621-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Arriaga-canon C, Contreras-espinosa L, Rebollar-vega R, Montiel-manríquez R, Cedro-tanda A, García-gordillo JA, Álvarez-gómez RM, Jiménez-trejo F, Castro-hernández C, Herrera LA. Transcriptomics and RNA-Based Therapeutics as Potential Approaches to Manage SARS-CoV-2 Infection. IJMS 2022;23:11058. [DOI: 10.3390/ijms231911058] [Reference Citation Analysis]
2 Mavragani CP, Skarlis C, Kostopoulos IV, Maratou E, Moutsatsou P, Terpos E, Tsitsilonis OE, Dimopoulos MA, Sfikakis PP. Distinct type I interferon responses between younger women and older men contribute to the variability of COVID-19 outcomes: Hypothesis generating insights from COVID-19 convalescent individuals. Cytokine 2022;157:155964. [PMID: 35868117 DOI: 10.1016/j.cyto.2022.155964] [Reference Citation Analysis]
3 Sánchez-montalvá A, Álvarez-sierra D, Martínez-gallo M, Perurena-prieto J, Arrese-muñoz I, Ruiz-rodríguez JC, Espinosa-pereiro J, Bosch-nicolau P, Martínez-gómez X, Antón A, Martínez-valle F, Riveiro-barciela M, Blanco-grau A, Rodríguez-frias F, Castellano-escuder P, Poyatos-canton E, Bas-minguet J, Martínez-cáceres E, Sánchez-pla A, Zurera-egea C, Teniente-serra A, Hernández-gonzález M, Pujol-borrell R; the “Hospital Vall d’Hebron Group for the study of COVID-19 immune profile”. Exposing and Overcoming Limitations of Clinical Laboratory Tests in COVID-19 by Adding Immunological Parameters; A Retrospective Cohort Analysis and Pilot Study. Front Immunol 2022;13:902837. [DOI: 10.3389/fimmu.2022.902837] [Reference Citation Analysis]
4 Ranea JAG, Perkins J, Chagoyen M, Díaz-Santiago E, Pazos F. Network-Based Methods for Approaching Human Pathologies from a Phenotypic Point of View. Genes (Basel) 2022;13:1081. [PMID: 35741843 DOI: 10.3390/genes13061081] [Reference Citation Analysis]
5 Tajuelo A, Carretero O, García-Ríos E, López-Siles M, Cano O, Vázquez M, Más V, Rodríguez-Goncer I, Lalueza A, López-Medrano F, Juan RS, Fernández-Ruiz M, Aguado JM, McConnell MJ, Pérez-Romero P. Brief Research Report: Virus-Specific Humoral Immunity at Admission Predicts the Development of Respiratory Failure in Unvaccinated SARS-CoV-2 Patients. Front Immunol 2022;13:878812. [PMID: 35547738 DOI: 10.3389/fimmu.2022.878812] [Reference Citation Analysis]
6 Townsend L, Dyer AH, Naughton A, Imangaliyev S, Dunne J, Kiersey R, Holden D, Mooney A, Leavy D, Ridge K, Sugrue J, Aldoseri M, Kelliher JH, Hennessy M, Byrne D, Browne P, Bacon CL, Doyle C, O’riordan R, Mclaughlin A, Bannan C, Martin-loeches I, White A, Mcloughlin RM, Bergin C, Bourke NM, O’farrelly C, Conlon N, Cheallaigh CN. Severe COVID-19 is characterised by inflammation and immature myeloid cells early in disease progression. Heliyon 2022;8:e09230. [DOI: 10.1016/j.heliyon.2022.e09230] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]